within Pharmacolibrary.Drugs.ATC.A;

model A10AD06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5e-07,
    adminDuration  = 600,
    adminMass      = 0.6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0001,
    k12             = 0.05,
    k21             = 0.05
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10AD06</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Insulin degludec and insulin aspart is a fixed-ratio co-formulation of two insulin analogs used in the management of diabetes mellitus. Insulin degludec is an ultra-long-acting basal insulin and insulin aspart is a rapid-acting prandial insulin. The combination is administered subcutaneously for glycaemic control in adults with diabetes mellitus. Both agents are approved and in current clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult individuals with type 1 and type 2 diabetes; parameters typically refer to healthy adult population or diabetic adults as studied in published population pharmacokinetic analyses.</p><h4>References</h4><ol><li><p>Liu, H, et al., &amp; Yu, Y (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. <i>Drug design, development and therapy</i> 19 2863–2871. DOI:<a href=\"https://doi.org/10.2147/DDDT.S500347\">10.2147/DDDT.S500347</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40236299/\">https://pubmed.ncbi.nlm.nih.gov/40236299</a></p></li><li><p>Biester, T, et al., &amp; Haahr, H (2016). Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes. <i>Pediatric diabetes</i> 17(8) 642–649. DOI:<a href=\"https://doi.org/10.1111/pedi.12358\">10.1111/pedi.12358</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26782928/\">https://pubmed.ncbi.nlm.nih.gov/26782928</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10AD06;
